Your browser doesn't support javascript.
loading
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Poon, Evon; Liang, Tong; Jamin, Yann; Walz, Susanne; Kwok, Colin; Hakkert, Anne; Barker, Karen; Urban, Zuzanna; Thway, Khin; Zeid, Rhamy; Hallsworth, Albert; Box, Gary; Ebus, Marli E; Licciardello, Marco P; Sbirkov, Yordan; Lazaro, Glori; Calton, Elizabeth; Costa, Barbara M; Valenti, Melanie; De Haven Brandon, Alexis; Webber, Hannah; Tardif, Nicolas; Almeida, Gilberto S; Christova, Rossitza; Boysen, Gunther; Richards, Mark W; Barone, Giuseppe; Ford, Anthony; Bayliss, Richard; Clarke, Paul A; De Bono, Johann; Gray, Nathanael S; Blagg, Julian; Robinson, Simon P; Eccles, Suzanne A; Zheleva, Daniella; Bradner, James E; Molenaar, Jan; Vivanco, Igor; Eilers, Martin; Workman, Paul; Lin, Charles Y; Chesler, Louis.
  • Poon E; Division of Clinical Studies and.
  • Liang T; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Jamin Y; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
  • Walz S; Division of Radiotherapy and Imaging, ICR, London, United Kingdom.
  • Kwok C; Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany.
  • Hakkert A; Division of Clinical Studies and.
  • Barker K; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Urban Z; Division of Clinical Studies and.
  • Thway K; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Zeid R; Division of Clinical Studies and.
  • Hallsworth A; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Box G; Division of Clinical Studies and.
  • Ebus ME; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Licciardello MP; Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Sbirkov Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Lazaro G; Division of Clinical Studies and.
  • Calton E; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Costa BM; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Valenti M; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.
  • De Haven Brandon A; Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Webber H; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Tardif N; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.
  • Almeida GS; Division of Clinical Studies and.
  • Christova R; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Boysen G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Richards MW; Division of Clinical Studies and.
  • Barone G; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Ford A; Division of Clinical Studies and.
  • Bayliss R; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Clarke PA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • De Bono J; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.
  • Gray NS; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Blagg J; Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom.
  • Robinson SP; Division of Clinical Studies and.
  • Eccles SA; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Zheleva D; Division of Clinical Studies and.
  • Bradner JE; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Molenaar J; Division of Clinical Studies and.
  • Vivanco I; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom.
  • Eilers M; Division of Radiotherapy and Imaging, ICR, London, United Kingdom.
  • Workman P; Division of Clinical Studies and.
  • Lin CY; Division of Clinical Studies and.
  • Chesler L; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
J Clin Invest ; 130(11): 5875-5892, 2020 11 02.
Article en En | MEDLINE | ID: mdl-33016930
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenosina / Quinasa 9 Dependiente de la Ciclina / Quinasa 2 Dependiente de la Ciclina / Proteína Proto-Oncogénica N-Myc / Temozolomida / Neuroblastoma Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenosina / Quinasa 9 Dependiente de la Ciclina / Quinasa 2 Dependiente de la Ciclina / Proteína Proto-Oncogénica N-Myc / Temozolomida / Neuroblastoma Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article